Filing Flows › Puma Biotechnology (PBYI) › Q2 2026 › vs Q2 2025
Puma Biotechnology (PBYI) Q2 2026 vs Q2 2025 (year over year)
Puma Biotechnology's revenue rose $4.1M (+8%) from $52.4M in Q2 2025 to $56.5M in Q2 2026. The biggest changes: Product +$4.4M (+9%); Royalty −$306K (-9%). Operating margin 13.4% against 12.7% (+0.8 pts).
Puma Biotechnology, Q2 2026: revenue $56.5M (+8% year over year), operating margin 13.4%, net earnings $8.2M, operating cash flow $1.6M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 13.4% | 12.7% | +0.8 pts |
| Net margin | 14.5% | 11.2% | +3.3 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Product | $53.6M | $49.2M | $4.4M | +9% |
| Royalty | $2.9M | $3.2M | −$306K | -9% |
| Revenue | $56.5M | $52.4M | $4.1M | +8% |
| Other income, net | $660K | −$471K | $1.1M | — |
| Operating profit | $7.6M | $6.6M | $949K | +14% |
| Costs & expenses | $48.9M | $45.8M | $3.1M | +7% |
| Pre-tax earnings | $8.2M | $6.2M | $2.1M | +34% |
| Cost of revenue | $12.5M | $12.3M | $174K | +1% |
| Research & development | $18.9M | $15.5M | $3.4M | +22% |
| SG&A | $17.5M | $18.0M | −$500K | -3% |
| Net earnings | $8.2M | $5.9M | $2.3M | +40% |
| Income tax | $56K | $310K | −$254K | -82% |
| Operating cash sources | $12.7M | $10.2M | $2.4M | +24% |
| Depreciation & amortization | $2.5M | $2.8M | −$247K | -9% |
| Share-based compensation | $2.0M | $1.6M | $325K | +20% |
| Working capital & other | $11.0M | −$3.8M | $14.9M | — |
| Operating cash flow | $1.6M | $14.1M | −$12.5M | -88% |
Questions
How much did Puma Biotechnology's revenue grow year over year in Q2 2026?
Puma Biotechnology's revenue rose $4.1M (+8%) from $52.4M in Q2 2025 to $56.5M in Q2 2026.
What drove Puma Biotechnology's revenue change in Q2 2026?
Product +$4.4M (+9%); Royalty −$306K (-9%).